US Stock MarketDetailed Quotes

LLY Eli Lilly and Co

Watchlist
  • 772.000
  • -1.840-0.24%
Close Dec 31 16:00 ET
  • 775.500
  • +3.500+0.45%
Pre 04:06 ET
732.87BMarket Cap83.46P/E (TTM)

Eli Lilly and Co Key Stats

Eli Lilly and Co Q3 2024 Earnings Date

Overview | Lilly reported revenue of $11.4 billion, a 20% year-over-year increase, along with earnings per share (EPS) of $1.18, which fell short of Wall Street estimates

Currency:USDOct 30, 2024

Estimate
(YoY)
Actual
(YoY)
Vs Estimate
(% Chg)
Revenue
12.12B
11.44B
-679.50M
Miss Est.
+27.58%
+20.43%
-5.61%
EPS
1.54
1.07
-0.47
Miss Est.
+2677.80%
+1883.33%
-30.70%
Strong Buy

Jan 1, 2025

Eli Lilly and Co Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 3 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: USD

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 12.977B--
--2024/Q4-- / 13.981B--
Oct 30, 20242024/Q311.439B / 12.119B--
Aug 8, 20242024/Q211.303B / 9.968B--
Apr 30, 20242024/Q18.768B / 8.930B--
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 12.977B--
--2024/Q4-- / 13.981B--
Oct 30, 20242024/Q311.439B / 12.119B--
Aug 8, 20242024/Q211.303B / 9.968B
Apr 30, 20242024/Q18.768B / 8.930B--

Unlock Free Earnings Estimates

Eli Lilly and Co Earnings Reports

Read more

Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries

Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.

Analysis

Analyst Rating

Updated: Jan 1, 2025

Strong Buy

  • Buy

    90.00%
  • Hold

    10.00%
  • Sell

    0.00%

Price Target

No Data